|
|
 |
|
Viewing report
|
|
|
|
Chronic Obstructive Pulmonary Disease (COPD): KOL Insights on Treatment Practices and Unmet Needs
Sociable Pharma, Oct 2011, Pages: 99
In-depth primary research was conducted in the US and across Europe with seven key opinion leaders to understand how changes will impact therapy use in the future. During the European Respiratory Society's 2011 Annual Congress, opinion was also gauged on the impact that new clinical data for existing and pipeline products will have on treatment strategies employed by COPD specialists.
Understand key treatment trends based on the latest KOL insights including:
- Step-up approach to the management of COPD
- ULABA: a rival to LAMA therapy?
- LABA versus LAMA therapy: current and future use
Identify unmet needs, including:
- Managing adherence issues
- Managing patients with very severe COPD
- Treating COPD inflammation
- Management of exacerbations
- Effective treatments for Stage I mild COPD
Key features:
- 2 treatment maps & 6 treatment settings: A visual guide to the treatment of COPD, based on extensive primary and secondary research
- Analysis of current US/EU treatment practices involving 11 drug classes: Inhaled
SABA, Inhaled SAMA, single combination inhaler of SABA + SAMA, Inhaled LABA, Inhaled LAMA, combination inhaler of ICS + LABA, Phosphodiesterase-4 (PDE-4) inhibitor, oral corticosteroids, methylxanthine, antibiotics, alpha-1 antitrypsin augmentation therapy
- 9 unmet needs identified: Based on KOL interviews and literature research
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
